[A17-53] Etelcalcetide (secondary hyperparathyroidism) - Addendum to Commission A17-25

Last updated 17.11.2017

Project no.:
A17-53

Commission:
Commission awarded on 09.10.2017 by the Federal Joint Committee (G-BA).

Report type:
Addendum

Status:
Commission completed

Department/Division:
Drug Assessment

Topic:
Digestion, metabolism and hormones

Indication:

Secondary hyperparathyroidism

Result of dossier assessment:

Study 20120360: neither advantage nor disadvantage proven for etelcalcetide in comparison with cinacalcet

Note:

If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.

Federal Joint Committee (G-BA)

2017-11-17 A G-BA decision was published.

G-BA documents on this decision

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form